Vertex Sells Lexiva, Agenerase Royalties For $160M
This article was originally published in The Pink Sheet Daily
Executive Summary
Non-core assets bring in cash for HCV push and more.
You may also be interested in...
Vertex's Latest Finance Play: Selling Off EU Milestone Payments For Telaprevir
Curious announcement could presage a deal already in place or be an effort to draw competing bids.
Vertex's Latest Finance Play: Selling Off EU Milestone Payments For Telaprevir
Curious announcement could presage a deal already in place or be an effort to draw competing bids.
2008 Deals Of The Year
Each week, "The Pink Sheet" presents commentary on some of the most interesting new business deals, contributed by the editors of the IN VIVO blog. As 2008 came to a close, the editors nominated the following transactions as their top deals of the year. Feeling moved to weigh in with your own favorite? 1Full write-ups of each deal and IVB's poll can be found at: http://invivoblog.blogspot.com/search/label/DOTY